1 active not recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
Follow Antineoplastic Agents: new trials by email Literature Review of Antineoplastic Agents trials Research Report on Antineoplastic Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma nivolumab, BMS-986253, Stereotactic Body Radiotherapy (SBRT) - Melanoma, Unresectable Solid Tumors | Phase 1 | Active not recruiting | Yana Najjar | 50 | 2021-11-29 | 2026-08-20 |
Melanoma (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1)
Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Neuroectodermal Tumors (1) · Neuroendocrine Tumors (1) · Nevi and Melanomas (1) · Skin Diseases (1) · Skin Neoplasms (1) · Skin and Connective Tissue Diseases (1)
HuMax-IL8 (1) · Nivolumab (1) · Radiosurgery (1) · spartalizumab (1)
Yana Najjar (1)
United States (1)